Aims and Scope
Anti-Cancer Drugs is an international medical journal, which aims to promote and encourage research on anti-cancer agents. It was first published in 1990 and it includes reports on clinical and experimental research results, from conventional cytotoxic chemotherapy to hormonal or biological response modalities. The journal has 10 issues per year and the current editor in chief is Mels Sluyser. According to the 2014 Journal Citation Reports, the journal has an impact factor of 1.784, ranking it 164th out of 211 in the category Oncology and 162nd out of 254 in the category Pharmacology & Pharmacy.
Key Metrics
5.2
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
98
H index
H-Index
Journal's h-index reflects the collective citation impact of the authors publishing in the journal. The h-index is defined as the maximum value of h such that the given journal has published at least h papers that have each been cited at least h times.
0.9
5-Year SI
5-year SI
- N/A 2-year SI
- 0.89 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q3
Oncology
SJR
- Q3 Oncology
- Q3 Pharmacology
- Q4 Cancer Research
- Q3 Pharmacology (medical)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
0.52
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Topics Covered
- Cell growth
- Colorectal cancer
- Overall survival
- Lung cancer
- Hepatocellular carcinoma
- Vinpocetine
- Cisplatin
- Cell cycle
- Reactive oxygen species
- Toxicity
- Epidermal growth factor receptor
- Squamous cell lung cancer
- Hysterectomy
- Breast cancer
- Autophagy
- Polymeric nanoparticles
- Glioblastoma
- Diffuse large B-cell lymphoma
- Western blot
- Tyrosine kinase
Journal Specifications
| Overview | |
| Publisher | LIPPINCOTT WILLIAMS & WILKINS |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1990 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Anti-Cancer Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Utidelone plus pembrolizumab as the fourth-line combination treatment in non-small cell lung cancer with EGFR mutation: a case report.
- 18 Oct 24
- Anti-cancer drugs
-
Full paper
Prophylactic role of pentoxifylline against paclitaxel-induced neuropathy among patients with breast cancer: a randomized-controlled trial.
- 16 Oct 24
- Anti-cancer drugs
-
Full paper
SMAC mimetic BV6 acts in synergy with mTOR inhibitor to increase cisplatin sensitivity in ovarian cancer.
- 16 Oct 24
- Anti-cancer drugs
-
Full paper
Combination of anlotinib and sintilimab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma: a single-arm prospective study
- 8 Oct 24
- Anti-Cancer Drugs
-
Full paper
Hyper-late major response after 5 years of nivolumab: role of treatment beyond progression in head and neck cancer.
- 1 Oct 24
- Anti-cancer drugs
-
Full paper
Individualized medication of venetoclax based on therapeutic drug monitoring in Chinese acute myeloid leukemia patients using an HPLC method.
- 1 Oct 24
- Anti-cancer drugs
Scite analysis
Powered by scite_
4.9k articles received 59.7k citations see all
- 2,242 Supporting
- 56,219 Mentioning
- 262 Contrasting
Editorial notices
- 5 Retractions
- 0 Withdrawals
- 2 Corrections
- 2 Errata
- 0 Expression of Concern
FAQs
How long has Anti-Cancer Drugs been actively publishing?
Anti-Cancer Drugs has been in operation since 1990 till date.
What is the publishing frequency of Anti-Cancer Drugs ?
Anti-Cancer Drugs published with a Monthly frequency.
How many articles did Anti-Cancer Drugs publish last years ?
In 2023, Anti-Cancer Drugs published 85 articles.
What is the eISSN & pISSN for Anti-Cancer Drugs ?
For Anti-Cancer Drugs,eISSN is 1473-5741 and pISSN is0959-4973.
What is Citescore for Anti-Cancer Drugs ?
Citescore for Anti-Cancer Drugs is 5.2.
What is H index for Anti-Cancer Drugs ?
H index for Anti-Cancer Drugs is 98.
What is SNIP score for Anti-Cancer Drugs ?
SNIP score for Anti-Cancer Drugs is 0.52.
What is the SJR for Anti-Cancer Drugs ?
SJR for Anti-Cancer Drugs is Q3.
Who is the publisher of Anti-Cancer Drugs ?
LIPPINCOTT WILLIAMS & WILKINS is the publisher of Anti-Cancer Drugs.